NEW YORK (GenomeWeb) – Cancer Genetics has reached a deal with Cantor Fitzgerald to sell up to $20 million of its common shares from time to time. 

The firm also said that its cash burn rate for the second quarter is anticipated to reach $4.8 million. 

In documents filed with the US Securities and Exchange Commission on Wednesday, Cancer Genetics said that the investment bank may sell shares deemed through an "at-the-market" offering, in which shares are offered at the prevailing market prices, or through other methods, including in privately negotiated transactions. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

Sponsored by

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.

Sponsored by

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sponsored by

This webinar will discuss an approach for automating variant classification based on the American College of Medical Genetics and Genomics guidelines.

Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.